Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets

John M. Mariadason(Olivia Newton-John Cancer Wellness & Research Centre)

iScience

November 1, 2019

10.1016/j.isci.2019.10.044

Cited by 22

Related Papers

Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer

|Oral Oncology|2012|91

Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells

|Molecular Cancer Therapeutics|2016|89

DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis

|Scientific Reports|2018|19